The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene

Cancer Research

Volumn 58, Issue 22, 1998, Pages 5144-5150

  Hogan, Kevin T ^a   Eisinger, Dominic P ^b   Cupp III, Samuel B ^a   Lekstrom, Kristen J ^a   Deacon, Donna D ^c   Shabanowitz, Jeffrey ^d   Hunt, Donald F ^c,d   Engelhard, Victor H ^a   Slingluff Jr , Craig L ^c   Ross, Mark M ^a  

^a Argonex Pharmaceuticals   (United States)

^b University of Virginia ^*

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELONGATION FACTOR; HLA ANTIGEN;

AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ANTIGEN RECOGNITION; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DNA SEQUENCE; GENE MUTATION; HUMAN; HUMAN CELL; LUNG CANCER; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SQUAMOUS CELL CARCINOMA;

ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A ANTIGENS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE ELONGATION FACTORS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032533507     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Slovin, S. F., Lackman, R. D., Ferrone, S., Kiely, P. E., and Mastrangelo, M. J. Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotypes, and specificity. J. Immunol., 137: 3042-3048, 1987.
2. Schendel, D. J., Gansbacher, B., Oberneder, R., Kriegmair, M., Hofstetter, A., Riethmuller, G., and Segurado, O. G. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J. Immunol., 151: 4209-4220, 1993.
3. Jacob, L., Somasundaram, R., Smith, W., Monos, D., Basak, S., Marincola, F., Pereira, S., and Herlyn, D. Cytotoxic T-cell clone against rectal carcinoma induced by stimulation of a patient's peripheral blood mononuclear cells with autologous cultured tumor cells. Int. J. Cancer, 71: 325-332, 1997.
4. Ioannides, C. G., Freedman, R. S., Platsoucas, C. D., Rashed, S., and Kim, Y. P. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J. Immunol., 146: 1700-1707, 1991.
5. Peoples, G. E., Schoof, D. D., Andrews, J. V., Goedegebuure, P. S., and Eberlein, T. J. T-cell recognition of ovarian cancer. Surgery, 114: 227-234, 1993.
6. Wolfel, T., Herr, W., Coulie, P., Schmitt, U., Meyer zum Buschenfelde, K. H., and Knuth, A. Lysis of human pancreatic adenocarcinoma cells by autologous HLA class I-restricted cytolytic T-lymphocyte (CTL) clones. Int. J. Cancer, 54: 636-644, 1993.
7. Peiper, L., Goedegebuure, P. S., Linehan, D. C., Ganguly, E., Douville, C. C., and Eberlein, T. J. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Eur. J. Immunol., 27: 1115-1123, 1997.
8. Yasumura, S., Hirabayashi, H., Schwartz, D. R., Toso, J. F., Johnson, J. T., Herberman, R. B., and Whiteside, T. L. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck. Cancer Res., 53: 1461-1468, 1993.
9. Slingluff, C. L., Jr., Cox, A. L., Stover, J. M., Jr., Moore, M. M., Hunt, D. F., and Engelhard, V. H. Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res., 54: 2731-2737, 1994.
10. Yoshino, I., Goedegebuure, P. S., Peoples, G. E., Parikh, A. S., DiMaio, J. M., Lyerly, H. K., Gazdar, A. F., and Eberlein, T. J. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res., 54: 3387-3390, 1994.
11. Boon, T., Cerottini, J. C., Van Pel, A., and van der Bruggen, P. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol., 12: 337-365, 1994.
12. Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D. J., Wei, J. P., and White, D. E. Use of tumor-infiltrating lymphocytes and interleukin 2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med., 319: 1676-1680, 1988.
13. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Kast, W. M., DeLeo, A. B., and Lotze, M. T. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med., 1: 1297-1302, 1995.
14. Celluzzi, C. M., Mayordomo, J. I., Storkus, W. J., Lotze, M. T., and Falo, L. D. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med., 183: 283-287, 1996.
15. Zitvogel, L., Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., and Storkus, W. J. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells. B7 costimulation and T helper cell 1-associated cytokines. J. Exp. Med., 183: 87-97, 1996.
16. Engelhard, V. H. Structure of peptides associated with class I and class II MHC molecules. Annu. Rev. Immunol., 12: 181-207, 1994.
17. Wolfel, T., Van Pel, A., Brichard, V., Schneider, J., Seliger, B., zum Buschenfelde, K. H. M., and Boon, T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol., 24: 759-764, 1994.
18. Gaugler, B., Van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J. J., De Plaen, E., Lethe, B., Brasseur, F., and Boon, T. Human gene MAGE-3 codes for an antigen recognized on melanoma by autologous cytolytic T lymphocytes. J. Exp. Med., 179: 921-930, 1994.
19. van der Bruggen, P., Bastin, J., Gajewski, T., Coulie, P. G., Boel, P., de Smet, C., Traversari, C., Townsend, A., and Boon, T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol., 24: 3038-3043, 1994.
20. Van den Eynde, B., Peeters, O., De Backer, O., Gaugler, B., Lucas, S., and Boon, T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med., 182: 689-698, 1995.
21. Brichard, V. G., Herman, J., Van Pel, A., Wildmann, C., Gaugler, B., Wolfel, T., Boon, T., and Lethe, B. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur. J. Immunol., 26: 224-230, 1996.
22. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J. Exp. Med., 180: 347-352, 1994.
23. Kawakami, Y., Eliyahu, S., Delgaldo, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., and Rosenberg, S. A. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA, 91: 6458-6462, 1994.
24. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P. F., Sette, A., Appella, E., and Rosenberg, S. A. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol., 154: 3961-3968, 1995.
25. Kang, X., Kawakami, Y., el-Gamil, M., Wang, R., Sakaguchi, K., Yannelli, J. R., Appella, E., Rosenberg, S. A., and Robbins, P. F. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J. Immunol., 155: 1343-1348, 1995.
26. Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Slingluff, C. L. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (Washington DC), 264: 716-719, 1994.
27. Skipper, J. C. A., Kittlesen, D. J., Hendrickson, R. C., Deacon, D. D., Harthun, N. L., Wagner, S. N., Hunt, D. F., Engelhard, V. H., and Slingluff, C. L. Shared epitopes for HLA-A3 restricted melanoma reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J. Immunol., 157: 5027-5033, 1996.
28. Castelli, C., Storkus, W. J., Maeurer, M. J., Martin, D. M., Huang, E. C., Pramanik, B. N., Nagabhushan, T. L., Parmiani, G., and Lotze, M. T. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J. Exp. Med., 181: 363-368, 1995.
29. Fisk, B., Blevins, T. L., Wharton, J. T., and Ioannides, C. G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med., 181: 2109-2117, 1995.
30. Fisk, B., Chesak, B., Pollack, M. S., Wharton, J. T., and Ioannides, C. G. Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. Cell. Immunol., 157: 415-427, 1994.
31. Ioannides, C. G., Fisk, B., Fan, D., Biddison, W. E., Wharton, J. T., and O'Brian, C. A. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell. Immunol., 151: 225-234, 1993.
32. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA, 92: 432-436, 1995.
33. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 3: 328-332, 1998.
34. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-327, 1998.
35. Hunt, D. F., Yates, J. R., Shabanowitz, J., Winston, S., and Hauer, C. R. Protein sequencing by tandem mass spectrometry. Proc. Natl. Acad. Sci. USA, 83: 6233-6237, 1986.
36. Hanes, J., Freudenstein, J., Rapp, G., and Schell, S. R. Construction of a plasmid containing the complete coding region of human elongation factor 2. Biol. Chem. Hoppe-Seyler, 373: 201-204, 1992.
37. Riis, B., Rattan, S. I. S., Clark, B. F. C., and Merrick, W. C. Eukaryotic protein elongation factors. Trends Biochem. Sci., 15: 420-424, 1990.
38. Coulie, P. G., Lehmann, F., Lethe, B., Herman, J., Lurquin, C., Andrawiss, M., and Boon, T. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA, 92: 7976-7980, 1995.
39. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (Washington DC), 269: 1281-1284, 1995.
40. Robbins, P. F., el-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E., and Rosenberg, S. A. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med., 183: 1185-1192, 1996.
41. Silver, M. L., Guo, H. C., Strominger, J. L., and Wiley, D. C. Atomic structure of a human MHC molecule presenting an influenza virus peptide. Nature (Lond.), 360: 367-369, 1992.
42. Slingluff, C. L., Jr., Cox, A. L., Henderson, R. A., Hunt, D. F., and Engelhard, V. H. Recognition of human melanoma cells by HLA-A2.1-restricted CTL is mediated by at least six shared peptide epitopes. J. Immunol., 150: 2955-2963, 1993.
43. + CTL. Int. J. Oncol., 10: 159-169, 1996.
44. + cytotoxic T lymphocytes. Cancer Res., 57: 87-93, 1997.
45. Skipper, J. C. A., Hendrickson, R. C., Gulden, P. H., Brichard, V., Van Pel, A., Chen, Y., Shabanowitz, J., Wolfel, T., Slingluff, C. L., Boon, T., Hunt, D. F., and Engelhard, V. H. An HLA-A2 restricted tyrosinase antigen on melanoma cells results from post-translational modification and suggests a novel processing pathway for membrane proteins. J. Exp. Med., 183: 527-534, 1996.
46. Meadows, L. R., Wang, W., den Haan, J. M., Blokland, E., Reinhardus, C., Drijfhout, J. W., Shabanowitz, J., Pierce, R., Agulnik, A., Bishop, C. E., Hunt, D. F., Goulmy, E., and Engelhard, V. H. The HLA-A*0201-restricted HY antigen contains a post-translationally modified cysteine that significantly affects T cell recognition. Immunity, 6: 273-281, 1997.
47. Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R., and Soltoff, S. Oncogenes and signal transduction. Cell, 64: 281-302, 1991.
48. Hunter, T. Cooperation between oncogenes. Cell, 64: 249-270, 1991.
49. Nakao, M., Yamana, H., Imai, Y., Toh, Y., Toh, U., Kimura, A., Yanoma, S., Kakegawa, T., and Itoh, K. HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res., 55: 4248-4252, 1995.
50. Mandruzzato, S., Brasseur, F., Andry, G., Boon, T., and van der Bruggen, P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med., 186: 785-793, 1997.